Taub Pam, Knight Michael G, McCarty Delilah, Robar Carey, Traina Andrea, Behnke Lyn
Division of Cardiovascular Medicine, University of California at San Diego, San Diego, CA, USA.
Department of Medicine, The George Washington University, Washington, DC, USA.
J Patient Exp. 2025 May 20;12:23743735251342141. doi: 10.1177/23743735251342141. eCollection 2025.
Atherosclerotic cardiovascular disease (ASCVD) and obesity pose challenges to patients, healthcare professionals (HCPs), and health systems. The aim of this study was to understand the journey of patients with ASCVD and obesity, their caregivers, and managing HCPs to optimize treatment outcomes. Patients with ASCVD and body mass index ≥ 27 kg/m (N = 61), their caregivers (N = 12), and HCPs (N = 24) were given an online survey and participated in 1:1 interviews. Cardiology HCPs (N = 120) were given a quantitative online survey. Despite the presence of risk factors, patients described little communication or urgency from their HCPs regarding the link between obesity and cardiovascular health prior to an ASCVD event. Cardiology HCPs ranked obesity as only the fourth most important parameter to monitor pre- and post-ASCVD event but were hesitant to prescribe antiobesity medications pre- and post-ASCVD despite new treatment options. In fact, only 12% recommended medication for weight management. Comprehensive HCP training on weight management and medication options as well as training on strategies to communicate these options to patients and involve them in their own treatment decisions may improve patient experiences and lead to improved health outcomes in patients with obesity and ASCVD.
动脉粥样硬化性心血管疾病（ASCVD）和肥胖给患者、医护人员（HCP）及卫生系统带来了挑战。本研究的目的是了解ASCVD合并肥胖患者、其护理人员以及负责管理的医护人员的治疗过程，以优化治疗效果。对ASCVD且体重指数≥27 kg/m²的患者（N = 61）、其护理人员（N = 12）以及医护人员（N = 24）进行了在线调查，并参与了一对一访谈。对心脏病学医护人员（N = 120）进行了定量在线调查。尽管存在风险因素，但患者表示在ASCVD事件发生之前，医护人员很少就肥胖与心血管健康之间的联系与他们沟通或强调其紧迫性。心脏病学医护人员将肥胖列为ASCVD事件前后监测的第四重要参数，但尽管有新的治疗选择，他们在ASCVD事件前后都不愿开具抗肥胖药物。事实上，只有12%的人推荐使用药物进行体重管理。对医护人员进行关于体重管理和药物选择的全面培训，以及关于向患者传达这些选择并让他们参与自身治疗决策的策略培训，可能会改善患者体验，并改善肥胖合并ASCVD患者的健康结局。
